National and international developments in cancer, health and policy. Produced in collaboration with the Press Association unless otherwise stated.
Atezolizumab used in combination with nab-paclitaxel is the first immunotherapy available for triple negative breast cancer.
A targeted cancer drug, already licensed for treating some breast and ovarian cancers, is found to be effective for some men with advanced prostate cancer.
A new combination therapy for adults with an aggressive type of non-Hodgkin lymphoma has not been recommended for NHS use in England.
New ‘chemotherapy-free’ treatment for follicular lymphoma approved for NHS use in England.
A new kidney cancer drug combination of pembrolizumab with axitinib gets an initial no for the NHS in England